The $2 Billion Filing Error In March 2000, the USPTO denied a patent term extension application filed by Pfizer for […]

The Name Behind the Molecule Every drug in clinical use has at least three names. There is the brand name,

Section 1: The Strategic Calculus of a Paragraph IV Challenge The decision to initiate a Paragraph IV (Para IV) challenge

The pharmaceutical industry is entering a historic super-cycle of patent expirations between 2025 and 2030.1 During this window, an estimated

The Race Nobody Wins Every year, dozens of generic manufacturers file ANDAs for the same thirty drugs. They spend millions

The Forecast That Keeps Getting Wrong Every year, Wall Street analysts publish revenue forecasts for major pharmaceutical products that prove

The most profitable single legal filing in American commerce is not an M&A deal, a securities offering, or a licensing

A deep-dive guide for investors, analysts, and executives who need to anticipate — not react to — patent expirations that

Introduction: Beyond Legal Formalities — Patents as the Cornerstone of Commercial Strategy A single, well-crafted drug patent strategy can be